Beta-glucans and cancer: The influence of inflammation and gut peptide

European Journal of Medicinal Chemistry

Volumn 142, Issue , 2017, Pages 486-492

  Baldassano, Sara ^a   Accardi, Giulia ^a   Vasto, Sonya ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

Cancer; Ghrelin; GLP 1; GLP 2; Glucose; Inflammation; Insulin; PYY; Glucans

Indexed keywords

BETA GLUCAN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; PEPTIDE YY;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; DIETARY FIBER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASM; NONHUMAN; OBESITY; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANALYSIS; ANIMAL; FUNCTIONAL FOOD; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; BETA-GLUCANS; FUNCTIONAL FOOD; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INFLAMMATION; NEOPLASMS; PEPTIDE YY;

EID: 85030469625     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2017.09.013     Document Type: Review

References (104)

1. Lattimer, J.M., Haub, M.D., Effects of dietary fiber and its components on metabolic health. Nutrients 2:12 (2010 Dec), 1266–1289, 10.3390/nu2121266.
2. Peterson, D.M., Genotype and environment effects on oat beta-glucan concentration. Crop Sci. 31 (1991), 1517–1520, 10.2135/cropsci1991.0011183X003100060025x.
3. Prasad, M.S., Madhu, C.H., Venkateshwalu, G., Sabath, M., Quantitative evaluation of carbohydrate levels in different natural foodstuffs by UV–visible spectrophometer. Asian J. Pharm. Anal. 2 (2012), 10–11.
4. Mo, L., Chen, Y., Li, W., Guo, S., Wang, X., An, H., Zhan, Y., Anti-tumor effects of (1→3)-β-d-glucan from Saccharomyces cerevisiae in S180 tumor-bearing mice. Int. J. Biol. Macromol. 95 (2017 Feb), 385–392, 10.1016/j.ijbiomac.2016.10.106.
5. Mo, L., Chen, Y., Li, W., Guo, S., Wang, X., An, H., Zhan, Y., Anti-tumor effects of (1→3)-β-d-glucan from Saccharomyces cerevisiae in S180 tumor-bearing mice. Int. J. Biol. Macromol. 95 (2017 Feb), 385–392, 10.1016/j.ijbiomac.2016.10.106.
6. Huang, W.J., Influences of gut hormones on hepatocellular carcinoma. Endocrinol. Metab. Synd., 4, 2015, 1, 10.4172/2161-1017.1000155.
7. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and allergies. EFSA J., 9, 2011, 2207, 10.2903/j.efsa.2011.2207.
8. Augustin, L.S., Libra, M., Crispo, A., Grimaldi, M., De Laurentiis, M., Rinaldo, M., D'Aiuto, M., Catalano, F., Banna, G., Ferrau, F., Rossello, R., Serraino, D., Bidoli, E., Massarut, S., Thomas, G., Gatti, D., Cavalcanti, E., Pinto, M., Riccardi, G., Vidgen, E., Kendall, C.W., Jenkins, D.J., Ciliberto, G., Montella, M., Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer, 17(1), 2017 Jan 23, 69, 10.1186/s12885-017-3064-4.
9. Abe, H., Aida, Y., Ishiguro, H., Yoshizawa, K., Miyazaki, T., Itagaki, M., Sutoh, S., Aizawa, Y., Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World J. Gastroenterol. 19:1 (2013 Jan 7), 78–85, 10.3748/wjg.v19.i1.78.
10. Brand-Miller, J., McMillan-Price, J., Steinbeck, K., Caterson, Makarem, N., Bandera, E.V., Lin, Y., Jacques, P.F., Hayes, R.B., Parekh, N., Carbohydrate nutrition and risk of adiposity-related cancers: results from the Framingham Offspring cohort. Br. J. Nutr. 2017:Jun 29 (1991-2013), 1–12, 10.1017/S0007114517001489.
11. Keum, N., Yuan, C., Nishihara, R., Zoltick, E., Hamada, T., Martinez Fernandez, A., Zhang, X., Hanyuda, A., Liu, L., Kosumi, K., Nowak, J.A., Jhun, I., Soong, T.R., Morikawa, T., Tabung FK,Qian, Z.R., Fuchs, C.S., Meyerhardt, J.A., Chan, A.T., Ng, K., Ogino, S., Giovannucci, E.L., Wu, K., Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. Int. J. Cancer 140:12 (2017 Jun 15), 2648–2656, 10.1002/ijc.30683.
12. Jenkins, D.J., Wolever, T.M., Taylor, R.H., Ghafari, H., Jenkins, A.L., Barker, H., Jenkins, M.J., Rate of digestion of foods and postprandial glycaemia in normal and diabetic subjects. Br. Med. J. 281:6232 (1980 Jul 5), 14–17.
13. Wolever, T.M.S., The insulin response to carbohydrate foods: critical evaluation of the insulinaemic index. Wolever TMS, the Glycaemic Index: a Physiological Classification of Dietary Carbohydrates, 2006, CAB International Oxford, UK (Chapter 3).
14. Wood, P.J., Oat and rye b-glucan: properties and function. Cereal Chem. 87 (2010), 315–330 doi org/10.1094/CCHEM-87-4-0315.
15. Behall, K.M., Scholfield, D.J., Hallfrisch, J.G., Barley b-glucan reduces plasma glucose and insulin responses compared with resistant starch in men. Nutr. Res., 26, 2006, 644e50.
16. Chandalia, M., Garg, A., Lutjohann, D., von Bergmann, K., Grundy, S.M., Brinkley, L.J., Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N. Engl. J. Med., 342, 2000, 1392e8.
17. Kristensen, M., Jensen, M.G., Dietary fibres in the regulation of appetite and food intake. Importance of viscosity. Appetite 56 (2011), 65–70, 10.1016/j.appet.2010.11.147.
18. Delzenne, N.M., Neyrinck, A.M., Cani, P.D., Gut microbiota and metabolic disorders: how prebiotic can work?. Br. J. Nutr. 109 (2013), S81–S85, 10.1017/S0007114512004047.
19. Seidel, D.V., Azcárate-Peril, M.A., Chapkin, R.S., Turner, N.D., Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk. Semin. Cancer Biol., 2017 Jul 1, 10.1016/j.semcancer.2017.06.009 pii: S1044–579X(17)30169-4.
20. Adam, C.L., Williams, P.A., Dalby, M.J., Garden, K., Thomson, L.M., Richardson, A.J., Gratz, S.W., Ross, A.W., Different types of soluble fermentable dietary fibre decrease food intake, body weight gain and adiposity in young adult male rats. Nutr. Metab. (Lond), 11, 2014 Aug 14, 36, 10.1186/1743-7075-11-36.
21. Takatori, E., Shoji, T., Miura, J., Takeuchi, S., Yoshizaki, A., Sugiyama, T., Case of peptide-YY-producing strumal carcinoid of the ovary: a case report and review. J. Obstet. Gynaecol. Res. 38:10 (2012 Oct), 1266–1270, 10.1111/j.1447-0756.2012.01859.x.
22. Huang, W.J., Influences of gut hormones on hepatocellular carcinoma. Endocrinol. Metab. Synd., 4(1), 2015 https://doi.org/10.4172/2161-1017.1000155.
23. Vasto, S., Carruba, G., Lio, D., Colonna-Romano, G., Di Bona, D., Candore, G., Caruso, C., Inflammation, ageing, and cancer. Mech. Ageing Dev. 130:1–2 (2008), 40–45, 10.1016/j.mad.2008.06.003 2009 Jan-Feb.
24. Maccalli, C., Parmiani, G., Ferrone, S., Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy. Immunol. Invest 46:3 (2017 Apr), 221–238, 10.1080/08820139.2017.1280051.
25. Asgari, M.M., Ray, G.T., Geier, J.L., Quesenberry, C.P., Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J. Am. Acad. Dermatol 76:4 (2017 Apr), 632–638, 10.1016/j.jaad.2016.10.006.
26. Kim, G.Y., Choi, G.S., Lee, S.H., Park, Y.M., Acidic polysaccharide isolated from Phellinus linteus enhances through the upregulation of nitric oxide and tumor necrosis factor-alpha from peritoneal macrophages. J. Ethnopharamacol 95 (2004), 69–76.
27. Javmen, A., Nemeikaitė-Čėnienė, A., Bratchikov, M., Grigiškis, S., Grigas, F., Jonauskienė, I., Zabulytė, D., Mauricas, M., β-glucan from Saccharomyces cerevisiae induces IFN-γ production in vivo in BALB/c mice. Vivo 29:3 (2015 May-Jun), 359–363.
28. Chan, G.C., Chan, W.K., Sze, D.M., The effects of beta-glucan on human immune and cancer cells. J. Hematol. Oncol., 2, 2009, 25, 10.1186/1756-8722-2-25.
29. Czop, J.K., Austen, K.F., A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J. Immunol. 134 (1985), 2588–2593.
30. Brown, G.D., Taylor, P.R., Reid, D.M., Willment, J.A., Williams, D.L., Martinez-Pomares, L., Wong, S.Y., Gordon, S., Dectin-1 is a major beta-glucan receptor on macrophages. J. Exp. Med. 196:3 (2002 Aug 5), 407–412.
31. Suram, S., Brown, G.D., Ghosh, M., Gordon, S., Loper, R., Taylor, P.R., Akira, S., Uematsu, S., Williams, D.L., Leslie, C.C., Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor. J. Biol. Chem. 281:9 (2006 Mar 3), 5506–5514.
32. Bose, N., Wurst, L.R., Chan, A.S., Dudney, C.M., LeRoux, M.L., Danielson, M.E., Will, P.M., Nodland, S.E., Patchen, M.L., Dalle Lucca, J.J., Lebeda, F.J., Vasilakos, J.P., Differential regulation of oxidative burst by distinct β-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells. Glycobiology 24:4 (2014 Apr), 379–391, 10.1093/glycob/cwu005.
33. Schorey, J.S., Lawrence, C., The pattern recognition receptor Dectin-1: from fungi to mycobacteria. Curr. Drug Targets 9 (2008), 123–129.
34. Goodridge, H.S., Simmons, R.M., Underhill, D.M., Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol. 178 (2007), 3107–3115.
35. Gross, O., Gewies, A., Finger, K., Schäfer, M., Sparwasser, T., Peschel, C., Förster, I., Ruland, J., Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442:7103 (2006 Aug 10), 651–656.
36. Rogers, N.C., Slack, E.C., Edwards, A.D., Nolte, M.A., Schulz, O., Schweighoffer, E., Williams, D.L., Gordon, S., Tybulewicz, V.L., Brown, G.D., Reis e Sousa, C., Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22:4 (2005 Apr), 507–517 Erratum in: Immunity. 2005 Jun;22(6):773-4.
37. Chan, W.K., Law, H.K., Lin, Z.B., Lau, Y.L., Chan, G.C., Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. Int. Immunol. 19 (2007), 891–899.
38. Liang, J., Melican, D., Cafro, L., Palace, G., Fisette, L., Armstrong, R., Patchen, Ml, Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol. 20 (1998), 595–614.
39. LeBlanc, B.W., Albina, J.E., Reichner, J.S., The effect of PGG- beta-glucan on neutrophil chemotaxis in vivo. J. Leukoc. Biol. 79 (2006), 667–675.
40. Novak, M., Vetvicka, V., Glucans as biological response modifiers. Endocr. Metab. Immune Disord. Drug Targets 9 (2009), 67–75.
41. Mo, L., Chen, Y., Li, W., Guo, S., Wang, X., An, H., Zhan, Y., Anti-tumor effects of (1→3)-β-d-glucan from Saccharomyces cerevisiae in S180 tumor-bearing mice. Int. J. Biol. Macromol. 95 (2017 Feb), 385–392, 10.1016/j.ijbiomac.2016.10.106.
42. Albeituni, S.H., Yan, J., The effects of β-glucans on dendritic cells and implications for cancer therapy. Anticancer Agents Med. Chem. 13:5 (2013 Jun), 689–698.
43. Hazama, S., Watanabe, S., Ohashi, M., Yagi, M., Suzuki, M., Matsuda, K., Yamamoto, T., Suga, Y., Suga, T., Nakazawa, S., Oka, M., Efficacy of orally administered superfine dispersed lentinan (β-1, 3-glucan)for the treatment of advanced colorectal cancer. Anticancer Res. 29 (2009), 2611–2617.
44. Demir, G., Klein, H., Mandel-Molinas, N., Tuzuner, N., Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int. Immunopharmacol. 7 (2007), 113–116, 10.1016/j.intimp.2006.08.011.
45. Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J.R., Gargano, M., Patchen, M.L., Walsh, R., Beliveau, M., Marier, J.F., Bose, N., Gorden, K., Schneller, F. 3rd, A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. Invest New Drugs 35:3 (2017 Jun), 345–358, 10.1007/s10637-017-0450-3.
46. Chan, A.S., Jonas, A., Qui, X., Ottoson, N.R., Walsh, R.M., Gorden, K.B., Harrison, B., Maimonis, P.J., Leonardo, S.M., Ertelt, K.E., Danielson, M.E., Michel, K.S., Nelson, M., Graff, J.R., Patchen, M.L., Bose, N., Imprime PGG-mediated anti-cancer immune activation requires immune complex formation. PLoS One, 11, 2016, 10.1371/journal.pone.0165909.
47. Amato, A., Baldassano, S., Caldara, G., Mulè, F., Neuronostatin: peripheral site of action in mouse stomach. Peptide 64C (2014), 8–13, 10.1016/j.peptides.2014.12.003.
48. Amato, A., Baldassano, S., Serio, R., Mulè, F., Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009), G678–G684, 10.1152/ajpgi.90587.2008.
49. Amato, A., Rotondo, A., Cinci, L., Baldassano, S., Vannucchi, M.G., Mulè, F., Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol. 299 (2010), G1038–G1044, 10.1152/ajpgi.00282.2010.
50. Baldassano, S., Liu, S., Qu, M.H., Mulè, F., Wood, J.D., Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in Guinea pig small intestine in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 297 (2009), G800–G805, 10.1152/ajpgi.00170.2009.
51. Rotondo, A., Amato, A., Lentini, L., Baldassano, S., Mule´, F., Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 32 (2011), 60–64, 10.1016/j.peptides.2010.09.028.
52. Baldassano, S., Bellanca, A.L., Serio, R., Mulè, F., Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. J. Endocrinol. 213 (2012), 277–284, 10.1530/JOE-12-0092.
53. Baldassano, S., Rappa, F., Amato, A., Cappello, F., Mulè, F., GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet. J. Cell Physiol. 230 (2015), 3029–3036, 10.1002/jcp.25039.
54. Baldassano, S., Amato, A., Caldara, G.F., Mulè, F., Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet. Endocrine 54:3 (2016 Dec), 648–656, 10.1007/s12020-016-0871-3.
55. Drucker, D.J., The role of gut hormones in glucose homeostasis. J. Clin. Invest 117 (2007), 24–32.
56. Nuzzo, D., Picone, P., Baldassano, S., Caruana, L., Messina, E., Marino Gammazza, A., Cappello, F., Mulè, F., Di Carlo, M., Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. Curr. Alzheimer Res. 12:8 (2015), 723–735.
57. Baldassano, S., Amato, A., Cappello, F., Rappa, F., Mulè, F., Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J. Endocrinol. 217:1 (2013 Mar 15), 11–20, 10.1530/JOE-12-0500.
58. Baldassano, S., Amato, A., Rappa, F., Cappello, F., Mulè, F., Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet. Endocr. Res. 41:4 (2016 Nov), 317–324.
59. Svendsen, B., Holst, J.J., Regulation of gut hormone secretion. Studies using isolated perfused intestines. Peptides, 2015, 10.1016/j.peptides.2015.08.001.
60. Parker, H.E., Gribble, F.M., Reimann, F., The role of gut endocrine cells in control of metabolism and appetite. Exp. Physiol. 99 (2014), 1116–1120, 10.1113/expphysiol.2014.079764.
61. Topping, D.L., Clifton, P.M., Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81 (2001), 1031–1064.
62. Kaji, I., Karaki, S., Tanaka, R., Kuwahara, A., Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J. Mol. Histol. 42 (2011), 27–38, 10.1007/s10735-010-9304-4.
63. Sleeth, M.L., Thompson, E.L., Ford, H.E., Zac-Varghese, S.E., Frost, G., Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutr. Res. Rev. 23 (2010), 135–145, 10.1017/S0954422410000089.
64. Tolhurst, G., Heffron, H., Lam, Y.S., Parker, H.E., Habib, A.M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., Gribble, F.M., Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:2 (2012 Feb), 364–371, 10.2337/db11-1019.
65. Vitaglione, P., Barone Lumaga, R., Stanzione, A., Scalfi, L., Fogliano, V., B-Glucan-enriched bread reduces energy intake and modifies plasma ghrelin and peptide YY concentrations in the short term. Appetite 53 (2009), 338–344, 10.1016/j.appet.2009.07.013.
66. Beck, E.J., Tapsell, L.C., Batterham, M.J., Tosh, S.M., Huang, X.F., Increases in peptide Y-Y levels following oat beta-glucan ingestion are dose-dependent inoverweight adults. Nutr. Res. 29 (2009), 705–709, 10.1016/j.nutres.2009.09.012.
67. Alderton, G.K., Tumour microenvironment: obesity promotes prostate cancer invasion. Nat. Rev. Cancer, 16(2), 2016 Jan 29, 70, 10.1038/nrc.2016.129.
68. Louie, S.M., Roberts, L.S., Nomura, D.K., Mechanisms linking obesity and cancer. Biochim. Biophys. Acta 1831:10 (2013 Oct), 1499–1508, 10.1016/j.bbalip.2013.02.008.
69. Berger, N.A., Obesity and cancer pathogenesis. Ann. N. Y. Acad. Sci. 1311 (2014 Apr), 57–76, 10.1111/nyas.12416.
70. Ryu, T.Y., Park, J., Scherer, P.E., Hyperglycemia as a risk factor for cancer progression. Diabetes Metab. J. 38:5 (2014 Oct), 330–336, 10.4093/dmj.2014.38.5.330.
71. Duan, W., Shen, X., Lei, J., Xu, Q., Yu, Y., Li, R., Wu, E., Ma, Q., Hyperglycemia, a neglected factor during cancer progression. Biomed. Res. Int., 2014, 2014, 461917, 10.1155/2014/461917.
72. Iyengar, N.M., Hudis, C.A., Dannenberg, A.J., Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66 (2015), 297–309, 10.1146/annurev-med-050913-022228.
73. van Kruijsdijk, R.C., van der Wall, E., Visseren, F.L., Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 18:10 (2009 Oct), 2569–2578, 10.1158/1055-9965.EPI-09-0372.
74. Persaud, S.J., Bewick, G.A., Peptide YY: more than just an appetite regulator. Diabetologia 57 (2014), 1762–1769, 10.1007/s00125-014-3292-y.
75. Manning, S., Batterham, R.L., The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu. Rev. Physiol. 76 (2014), 585–608, 10.1146/annurev-physiol-021113-170404.
76. Juvonen, K.R., Salmenkallio-Marttila, M., Lyly, M., Liukkonen, K.H., Lähteenmäki, L., Laaksonen, D.E., Uusitupa, M.I., Herzig, K.H., Poutanen, K.S., Karhunen, L.J., Semisolid meal enriched in oat bran decreases plasma glucose and insulin levels, but does not change gastrointestinal peptide responses or short-term appetite in healthy subjects. Nutr. Metab. Cardiovasc Dis. 21:9 (2011 Sep), 748–756, 10.1016/j.numecd.2010.02.002.
77. Essah, P.A., Levy, J.R., Sistrun, S.N., Kelly, S.M., Nestler, J.E., Effect of macronutrient composition on postprandial peptide YY levels. J. Clin. Endocrinol. Metab. 92 (2007), 4052–4055.
78. Barone Lumaga, R., Azzali, D., Fogliano, V., Scalfi, L., Vitaglione, P., Sugar and dietary fibre composition influence, by different hormonal response, the satiating capacity of a fruit-based and a β-glucan-enriched beverage. Food Funct. 3 (2012), 67–75, 10.1039/c1fo10065c.
79. Tseng, W.W., Liu, C.D., Peptide YY and cancer: current findings and potential clinical applications. Peptides 23:2 (2002 Feb), 389–395.
80. Adrian, T.E., Ballantyne, G.H., Zucker, K.A., Zdon, M.J., Tierney, R., Modlin, I.M., Lack of peptide YY immunoreactivity in adenomatous colonic polyps: evidence in favor of an adenoma-carcinoma sequence. J. Surg. Res. 44 (1988), 561–565.
81. Liu, C.D., Balasubramaniam, A., Saxton, R.E., Paiva, M., McFadden, D.W., Human pancreatic cancer growth is inhibited by peptide YY and BIM-43004–1. J. Surg. Res. 58 (1995), 707–712.
82. Reubi, C., Gugger, M., Waser, B., Co-expressed peptide receptors in breast cancer asb a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 29:7 (2002 Jul), 855–862.
83. Beck, E.J., Tosh, S.M., Batterham, M.J., Tapsell, L.C., Huang, X.F., Oat beta-glucan increases postprandial cholecystokinin levels, decreases insulin response and extends subjective satiety in overweight subjects. Mol. Nutr. Food Res. 53 (2009), 1343–1351, 10.1002/mnfr.200800343.
84. Pradhan, G., Samson, S.L., Sun, Y., Ghrelin: much more than a hunger hormone. Curr. Opin. Clin. Nutr. Metab. Care 16 (2013), 619–624, 10.1097/MCO.0b013e328365b9be.
85. Hartvigsen, M.L., Gregersen, S., Lærke, H.N., Holst, J.J., Bach Knudsen, K.E., Hermansen, K., Effects of concentrated arabinoxylan and β-glucan compared with refined wheat and whole grain rye on glucose and appetite in subjects with the metabolic syndrome: a randomized study. Eur. J. Clin. Nutr. 68 (2014), 84–90, 10.1038/ejcn.2013.236.
86. Sever, S., White, D.L., Garcia, J.M., Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. Endocr. Relat. Cancer 23 (2016), R393–R409, 10.1530/ERC-16-0130.
87. Ariyasu, H., Takaya, K., Tagami, T., Ogawa, Y., Hosoda, K., Akamizu, T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 86 (2001), 4753–4758, 10.1210/jcem.86.10.7885.
88. Waseem, T., Duxbury, M., Ito, H., Ashley, S.W., Robinson, M.K., Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 143 (2008), 334–342, 10.1016/j.surg.2007.09.039.
89. Shimizu, Y., Nagaya, N., Isobe, T., Imazu, M., Okumura, H., Hosoda, H., Kujima, M., Kangawa, K., Kehno, N., Increased plasma ghrelin level in lung cancer cachexia. Clin. Cancer Res. 9 (2003), 774–778.
90. Wolf, I., Sadetzki, S., Kanety, H., Kundel, Y., Pariente, C., Epstein, N., Oberman, B., Catane, R., Adiponectin ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106 (2005), 966–973.
91. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
92. Brubaker, P.L., Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128 (1991), 3175–3182.
93. Knauf, C., Cani, P.D., Kim, D.H., Iglesias, M.A., Chabo, C., Waget, A., Colom, A., Rastrelli, S., Delzenne, N.M., Drucker, D.J., Seeley, R.J., Burcelin, R., Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes 57:10 (2008 Oct), 2603–2612, 10.2337/db07-1788.
94. Rocca, A.S., Brubaker, P.L., Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140 (1999), 1687–1694.
95. Amato, A., Baldassano, S., Liotta, R., Serio, R., Mulè, F., Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. J. Endocrinol. 221 (2014), 29–37, 10.1530/JOE-13-0525.
96. Baldassano, S., Wang, G.D., Mule, F., Wood, J.D., Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in Guinea pig small intestine in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 302 (2012), G352–G358, 10.1152/ajpgi.00333.2011.
97. Ames, N., Blewett, H., Storsley, J., Thandapilly, S.J., Zahradka, P., Taylor, C., A double-blind randomised controlled trial testing the effect of a barley product containing varying amounts and types of fibre on the postprandial glucose response of healthy volunteers. Br. J. Nutr. 8 (2015), 1–11, 10.1017/S0007114515000367.
98. Bak, M.J., Wewer Albrechtsen, N.J., Pedersen, J., Knop, F.K., Vilsbøll, T., Jørgensen, N.B., Hartmann, B., Deacon, C.F., Dragsted, L.O., Holst, J.J., Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes. Metab. 16:11 (2014 Nov), 1155–1164, 10.1111/dom.12352.
99. Baldassano, S., Amato, A., GLP-2: what do we know? What are we going to discover?. Regul. Pept. 194–195 (2014), 6–10, 10.1016/j.regpep.2014.09.002.
100. Jeppesen, P.B., Pertkiewicz, M., Messing, B., Iyer, K., Seidner, D.L., O'keefe, S.J., Forbes, A., Heinze, H., Joelsson, B., Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 143:6 (2012 Dec), 1473–1481, 10.1053/j.gastro.2012.09.007 e3.
101. Hou, Y., Ernst, S.A., Heidenreich, K., et al. Glucagon-like peptide −1 receptor is present in pancreatic cancer cells and regulates amylase secretion through cAMP. Am. J. Physiol. Gastrointest. Liver Physiol. 310:1 (2016), G26–G33.
102. Ligumsky, H., Wolf, I., Israeli, S., Haimsohn, M., Ferber, S., Karasik, A., Kaufman, B., Rubinek, T., The peptide-hormone glucagonlike peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res. Treat. 132:2 (2012), 449–461.
103. Luciani, P., Deledda, C., Benvenuti, S., Squecco, R., Cellai, I., Fibbi, B., Marone, I.M., Giuliani, C., Modi, G., Francini, F., Vannelli, G.B., Peri, A., Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells. PLoS One, 8(8), 2013, e71716.
104. Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., Tanaka, T., Mizoguchi, M., Nabeshima, K., Tanaka, M., Yanase, T., Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 63:11 (2014 Nov), 3891–3905, 10.2337/db13-1169.